Turning Science Into Products™

SynDevRx™, Inc. is a venture-backed company developing best-in-class novel polymer-based drug conjugates which are designed to improve the activity, delivery and safety of small molecule drugs making them more likely to receive FDA approval.  We believe our superior polymer-drug linking chemistries significantly improve bio-distribution, activity and safety of polymer-drug conjugates and provide a solution to both the insufficient activity and off-target toxicities which cause most small molecule drugs to fail in clinical trials.

Our technology concentrates small molecule activity at the disease site with predictable and reliable physical properties that can speed up development time and lower costs while improving the PK profile and increasing a drug's therapeutic index.

Our lead drug candidate inhibits MetAP2 - an enzyme which independent research has shown to be key to tumor growth, proliferation and metastasis.  It has shown compelling activity and safety with a surprisingly large therapeutic index in pre-clinical animal experiments.

Our proprietary technology enhances small molecule activity by specifically delivering and releasing the API (active pharmaceutical ingredient) in the the target diseased tissue. Keeping the active drug sequestered and out of general circulation is seen as an effective way to greatly reduce toxicities associated with other polymer-drug conjugates that undergo non-specific hydrolytic degradation as well as common small molecule drugs that have general bio-distribution.